Literature DB >> 25056122

RB family tumor suppressor activity may not relate to active silencing of E2F target genes.

Tinke L Vormer1, Kamila Wojciechowicz1, Marleen Dekker1, Sandra de Vries1, Anja van der Wal1, Elly Delzenne-Goette1, Sjalin H Naik2, Ji-Ying Song3, Jan-Hermen Dannenberg1, Jacob B Hansen4, Hein Te Riele5.   

Abstract

The retinoblastoma protein pRB and its two homologs p130 and p107 form the family of pocket proteins and play a major role in cell-cycle regulation and suppression of human and mouse tumorigenesis. Pocket proteins regulate the activity of E2F transcription factors during G1-S transition. Two mechanisms have been described: (i) pocket protein binding blocks the transactivation domain of activator E2Fs, inhibiting E2F-dependent transcription and (ii) E2F-bound pocket proteins can recruit chromatin remodeling proteins containing an LxCxE motif (x encoding any amino acid), resulting in active repression of E2F target genes. To investigate the importance of pRB's LxCxE-interacting motif in cell-cycle control and tumor suppression, we generated mouse embryonic fibroblasts and mice expressing a mutant pRB protein carrying an asparagine for phenylalanine substitution at position 750, abrogating LxCxE binding. Because p130 may compensate for loss of pRB, we studied pRB(N750F) activity in the presence and absence of p130. The pRB-LxCxE interaction was not required for cell-cycle arrest upon mitogen deprivation and cell-cell contact, but did contribute to RAS(V12)- and radiation-induced cell-cycle arrest. Remarkably, the pRB-LxCxE interaction was not required for suppression of in vitro and in vivo transformation, even in the absence of p130. These results indicate that pRB's tumor suppressor activity is not effectuated by active silencing of E2F target genes, but rather by regulation of activator E2Fs or another unidentified mechanism. Furthermore, the in vitro response of pocket protein-perturbed cells to mitogen deprivation and cell-cell contact seems a better predictor of tumor development than the response to ectopic RAS(V12) expression. Cancer Res; 74(18); 5266-76. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25056122     DOI: 10.1158/0008-5472.CAN-13-3706

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Role of cell cycle regulators in adipose tissue and whole body energy homeostasis.

Authors:  I C Lopez-Mejia; J Castillo-Armengol; S Lagarrigue; L Fajas
Journal:  Cell Mol Life Sci       Date:  2017-10-07       Impact factor: 9.261

2.  An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences.

Authors:  Charles A Ishak; Aren E Marshall; Daniel T Passos; Carlee R White; Seung J Kim; Matthew J Cecchini; Sara Ferwati; William A MacDonald; Christopher J Howlett; Ian D Welch; Seth M Rubin; Mellissa R W Mann; Frederick A Dick
Journal:  Mol Cell       Date:  2016-11-23       Impact factor: 17.970

3.  The retinoblastoma protein: multitasking to suppress tumorigenesis.

Authors:  Tinke L Vormer; Jacob B Hansen; Hein Te Riele
Journal:  Mol Cell Oncol       Date:  2015-01-26

4.  The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.

Authors:  Minxia Liu; Kecheng Zhou; Yunchao Huang; Yi Cao
Journal:  J Exp Clin Cancer Res       Date:  2015-10-14

5.  Multiple molecular interactions redundantly contribute to RB-mediated cell cycle control.

Authors:  Michael J Thwaites; Matthew J Cecchini; Srikanth Talluri; Daniel T Passos; Jasmyne Carnevale; Frederick A Dick
Journal:  Cell Div       Date:  2017-03-14       Impact factor: 5.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.